Shaping the future of Type 2 Diabetes care
DRG Disease Landscape & Forecast
Type 2 Diabetes – Landscape & Forecast – Disease Landscape & Forecast (G7)
This report provides a forward-looking analysis of the T2D market, exploring key trends driving growth through 2033—including the rising use of nonglycemic therapies and novel treatment classes. With expert commentary and extensive data, it highlights the impact of major market shifts, such as loss of exclusivity for leading brands and the uptake of first-in-class innovations like Mounjaro, offering the strategic foresight needed to navigate this complex and evolving landscape.
Request more information
Key trends in Type 2 Diabetes treatment:
- Market Expansion Driven by Polypharmacy: The T2D therapy market will continue to grow through 2033, fueled by increased use of combination treatments and later-line therapies that offer benefits beyond glycemic control.
- Downward Pressure from Loss of Exclusivity: Market sales will face headwinds due to the patent expirations of major drug classes, including DPP-IV inhibitors, SGLT-2 inhibitors and GLP-1 receptor agonists.
- Innovation in Incretin-Based Therapies: New entrants like Eli Lilly’s Mounjaro (GIP/GLP-1 receptor agonist) and other late-stage therapies are poised to offset some losses and reshape the treatment landscape.
- Unmet Need for Disease-Modifying Therapies: There remains a significant opportunity for treatments that not only manage symptoms but also modify disease progression and lessen the burden of complex therapy regimens.
Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.
Key questions answered:
-
What are the primary growth drivers and market constraints shaping the T2D landscape and how is the therapeutic market expected to evolve across the 10-year forecast period?
-
In what ways has the U.S. and Japan launch of Eli Lilly’s tirzepatide (Mounjaro) impacted the prescribing dynamics of established GLP-1 receptor agonists, including Eli Lilly’s Trulicity and Novo Nordisk’s Ozempic — and how is the therapy likely to be adopted in European markets?
-
How will the increasing availability of nonbranded therapies influence the competitive and pricing environment in the G7 T2D market?
-
What are leading diabetologists’ and endocrinologists’ perspectives on the clinical value and positioning of emerging assets such as Novo Nordisk’s insulin icodec and the CagriSema combination therapy?
Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.
Key highlights:
10-year market forecast (2023–2033)
Annualized detailed forecasts and treatment trends across the U.S., EU5, and Japan.
Granular epidemiological insights
Features prevalence data by country, with diagnosis and treatment rates segmented by population to support targeted market analysis.
Pipeline intelligence powered by Cortellis
Real-time updates on current and emerging therapies, including novel drug classes.
Primary research with 19 interviews with thought-leading endocrinologists and diabetologists
Experts' perspectives complemented by proprietary survey data from Clarivate’s broader research initiatives.
What is Disease Landscape & Forecast?
Disease Landscape & Forecast is a premier market intelligence platform, offering:
-
Comprehensive market data including world-class epidemiology, current and emerging therapy insights, and robust drug forecasts
-
Dynamic updates ensuring continuous enhancements to reflect indication-specific developments throughout the year
-
Real-time pipeline intelligence coming directly from Cortellis, with daily updates and interactive figures for in-depth analysis
Expert Insights on Type 2 Diabetes
Built on expert knowledge and rigorous research
- 19 thought-leading T2D specialists across the G7.
- Epidemiological modeling for Type 2 Diabetes populations.
- Real-time pipeline intelligence tracking the most promising therapies.
